Personalised digital therapy and self-management programme for the management of Irritable Bowel Syndrome

Bupa和NHS估计，英国15%-20%的人口受到肠易激综合征(IBS)的影响。IBS是一种长期的疾病，具有无法解释的症状，可能严重影响日常生活。该项目的目标是提供一套现成的、个性化的行为改变和减压工具，以支持IBS患者的自我治疗。Bold Health基于CBT对IBS的高效黄金标准干预发明了一款治疗移动应用Zemedy，该工具包含在NICE指南中，目前由治疗师在线下提供。Zemedy将指导用户进行治疗，以便能够以完全数字化、方便的规模和成本提供治疗。该项目的主要目的是获得真实世界的临床证据、用户反馈，并了解如何在NHS设置下开出和获得Zemedy。同时，还将设计获得采用Zemedy的益处的临床证据所需的临床试验，并制定研究方案。根据NHS的长期计划，Zemedy将协助NHS的数字化转型，提供数字启用和远程护理，使人们能够控制他们的治疗选择，并提供一种解决方案，允许患者在他们方便的时间和地点进行治疗。Zemedy将实现以患者为中心的IBS管理，帮助治疗依从性并加强治疗益处。该项目由Bold领导，将利用其与领先的IBS慈善IBS网络和Insight National IAPT服务的伙伴关系，在NHS环境下进行两个小型用户试验，以生成患者和临床医生的真实数据。这些将提供有关Zemedy在当前NHS临床路径中整合的基本数据和质量反馈，并建立患者和临床医生的可用性和可接受性。Zemedy的卫生经济评估也将由我们的分包商Cheata完成。该项目的成果将提供进行Zemedy必要的临床试验所需的垫脚石，以产生证据，使Zemedy能够在NHS范围内采用。

Bupa and the NHS estimate that 15-20% of the UK population is affected by Irritable Bowel Syndrome (IBS). IBS is a long-term condition with unexplained symptoms that can severely impact daily life. The objective of this project is to provide an at-hand, personalised, and set of behavioural-change and stress-reduction tools to support self-treatment for IBS sufferers.A treatment mobile app Zemedy has been invented by Bold Health, based on the highly effective gold standard intervention of CBT for IBS, which is included in the NICE guidelines and currently offered offline by therapists. Zemedy will guide users in their treatment such that it can be delivered fully digitally, conveniently at both scale and cost. The main aim of this project is to gain real-world clinical evidence, user-feedback and understanding how Zemedy could be prescribed and accessed within the NHS setting. In parallel, the clinical trial required to gain clinical evidence of the benefits of Zemedy adoption will also be designed and a research protocol developed.In line with the NHS long-term plan, Zemedy will assist with the Digital transformation of the NHS providing digitally enabled and remote care, empowering people to control their therapy options, with a solution that allows patients to undertake treatment at a time and place that is convenient for them. Zemedy will enable patient-centred management of IBS helping treatment compliance and reinforcing the treatment benefits.The project, led by Bold, will utilise its partnerships with leading IBS Charity IBS Network and with Insight national IAPT service to undertake two small user-trials within the NHS setting to generate real-world data, both with patients as well as clinicians. These will provide essential data and qualitative feedback regarding the integration of Zemedy within the current NHS Clinical pathway, and establish usability and acceptability to patients and clinicians. The Health Economic evaluation of Zemedy will also be completed by our sub-contractor CHEATA. The output of the project will provide the stepping-stones required to undertake the necessary clinical-trial of Zemedy to generate evidence that will enabling the adoption of Zemedy across the NHS.